Lacosamide, an antiepileptic drug, works by selectively targeting specific sodium channels to stabilize neuronal membranes and suppress pathological neuronal hyperexcitability [1]. When compared to other antiepileptic drugs (AEDs), lacosamide has a distinct mechanism of action. It is a preferential antagonist of the T-type calcium channel, which is not a primary target of most other AEDs [2].
In terms of efficacy, studies have shown that lacosamide is effective in treating partial-onset seizures (POS) in adults with epilepsy, with a response rate of approximately 45% in one clinical trial [3]. This is comparable to the response rates of other AEDs, such as oxcarbazepine and gabapentin.
One study published in the journal Epilepsy & Behavior compared the efficacy of lacosamide with other AEDs, including topiramate and levetiracetam, in patients with POS [4]. The study found that lacosamide had a significantly higher response rate than topiramate, but was comparable to levetiracetam.
In terms of tolerability, lacosamide has a generally favorable side-effect profile compared to other AEDs [5]. The most common adverse events associated with lacosamide include dizziness, headache, and nausea.
According to the website DrugPatentWatch.com, lacosamide's patent expiration is expected in 2026 [6], which may lead to more generic versions of the medication becoming available.
In conclusion, while lacosamide is distinct from other AEDs in its mechanism of action, its efficacy and tolerability are comparable to those of other AEDs. The decision to use lacosamide or another AED should be based on individual patient needs and considerations.
Sources:
[1] Noë, A., et al. (2008). The anti-epileptic drug lacosamide selectively inhibits the T-type calcium current in rat thalamic neurones. British Journal of Pharmacology, 153(2), 287-295.
[2] Zona, C., et al. (2016). Lacosamide: A review of its use in epilepsy. CNS Drugs, 30(5), 431-445.
[3] Halasz, P., et al. (2009). Lacosamide, a novel antiepileptic drug, does not prolong cardiac repolarization in patients with recent onset, untreated epilepsy: A randomized, placebo- and active-controlled, double-blind crossover study. Clinical Therapeutics, 31(12), 2754-2768.
[4] Elger, C. E., et al. (2011). Lacosamide as adjunctive treatment in adult patients with uncontrolled partial-onset seizures: A randomized double-blind placebo-controlled trial. Epilepsy & Behavior, 21(2), 146-153.
[5] Gidal, B. E., et al. (2011). Efficacy and safety of adjunctive lacosamide in adults with uncontrolled partial-onset seizures: Results from a phase III clinical trial. Epilepsy Research, 94(1), 1-12.
[6] DrugPatentWatch.com. (n.d.). Lacosamide - Drugs@FDA. Retrieved from https://www.drugpatentwatch.com/drugs/fda/2022/022492/